|
Lutetium Lu 177 Vipivotide Tetraxetan Clinical Trials
7 actively recruiting trials across 6 locations
Also known as: 177Lu-PSMA-617, 177Lu-labeled PSMA-617, AAA 617, AAA-617, AAA617 +5 more
Pipeline
Phase 1: 1Phase 2: 6
Top Sponsors
- Jonsson Comprehensive Cancer Center2
- University of Washington1
- Mayo Clinic1
- Fred Hutchinson Cancer Center1
- City of Hope Medical Center1
Indications
- Cancer7
- Stage IVB Prostate Cancer AJCC v86
- Castration-Resistant Prostate Carcinoma4
- Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v81
- Metastatic Castration-Resistant Prostate Adenocarcinoma1
Los Angeles, California2 trials
Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)
UCLA / Jonsson Comprehensive Cancer Center
Phase 2
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
UCLA / Jonsson Comprehensive Cancer Center
Phase 2
Tucson, Arizona1 trial
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Banner University Medical Center - Tucson
Phase 2
Duarte, California1 trial
177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
City of Hope Medical Center
Phase 1
San Francisco, California1 trial
Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
University of California San Francisco
Phase 2
Rochester, Minnesota1 trial
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Mayo Clinic in Rochester
Phase 2
Seattle, Washington1 trial
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Fred Hutch/University of Washington Cancer Consortium
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.